v3.25.0.1
Revenues from Contracts with Customers (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue From Contracts With Customers [Abstract]  
Summary of Disaggregation of Revenues from Contracts with Customers Set out below is the disaggregation of the Group’s revenues from contracts with customers:
Years ended December 31,
(in millions €)
2024
2023
2022
COVID-19 vaccine revenues
2,432.1
88%
3,776.2
99%
17,145.2
99%
Other revenues
319.0
12%
42.8
1%
165.4
1%
Total
2,751.1
100%
3,819.0
100%
17,310.6
100%
(in millions €)
Years ended December 31,
Revenues by customers
2024
2023
2022
Pfizer
2,011.7
73%
3,293.0
86%
13,795.8
80%
German Federal Ministry of Health
701.0
25%
473.6
12%
3,020.5
17%
Other customers
38.4
2%
52.4
2%
494.3
3%
Total
2,751.1
100%
3,819.0
100%
17,310.6
100%
(in millions €)
Years ended December 31,
Revenues by countries
2024
2023
2022
United States
1,847.8
67%
3,010.9
79%
12,709.7
73%
Germany
706.9
26%
482.7
13%
3,031.0
18%
Rest of the World
196.4
7%
325.4
8%
1,569.9
9%
Total
2,751.1
100%
3,819.0
100%
17,310.6
100%
The revenues from contracts with customers disclosed above were recognized as follows:
Years ended December 31,
(in millions €)
2024
2023
2022
Timing of revenue recognition
Goods and services transferred at a point in time
611.4
776.3
4,447.2
Goods and services transferred over time
298.5
15.4
127.2
Revenue recognition applying the sales-based or usage-based
royalty recognition constraint model(1)
1,841.2
3,027.3
12,736.2
Total
2,751.1
3,819.0
17,310.6
(1)Represents sales based on the share of the collaboration partners’ gross profit and sales milestones.
Disclosure of Contract Assets The contract assets developed as follows:
2024
2023
(in millions €)
Current
Non-
current
Total
Current
Non-
current
Total
As of January 1
4.9
—
4.9
—
—
—
Additions
—
28.4
28.4
4.2
—
4.2
thereof: attributable to performance
obligations satisfied in prior periods
—
23.6
23.6
—
—
—
Reclassification to trade accounts receivables
(13.5)
—
(13.5)
—
—
—
Reclassification from non-current to current
18.6
(18.6)
—
—
—
—
Changes in scope of consolidation
—
—
—
0.7
—
0.7
As of December 31
10.0
9.8
19.8
4.9
—
4.9
Contract Liabilities The development of the contract liabilities is as follows:
2024
2023
(in millions €)
Current
Non-
current
Total
Current
Non-
current
Total
As of January 1
353.3
398.5
751.8
77.1
48.4
125.5
Additions
—
—
—
387.2
444.0
831.2
Recognition as revenues
(272.7)
—
(272.7)
(202.2)
—
(202.2)
Reclassification from non-current to current
215.5
(215.5)
—
93.9
(93.9)
—
Currency effects
(1.2)
—
(1.2)
(2.7)
—
(2.7)
As of December 31
294.9
183.0
477.9
353.3
398.5
751.8
Summary of Revenue Recognized Set out below is the amount of revenue recognized for the periods indicated:
Years ended December 31,
(in millions €)
2024
2023
2022
Amounts included in contract liabilities at the beginning of the year
272.7
3.5
63.1